Several different chemotherapy drugs are used in the treatment of different subtypes of lymphoma, sometimes alone and other times in combination chemotherapy regimens.
The drugs a person receives depend entirely on his or her diagnosis, age and overall health.
Combination chemotherapy regimens are referred to by acronyms, with each letter representing a chemotherapeutic drug. Here we'll look at the drugs frequently used against diffuse large B-cell lymphoma, follicular lymphoma and Hodgkin's lymphoma. You can read more about each of the drugs by clicking on the name of the regimen.
Diffuse large B-cell lymphoma is the most frequently diagnosed B-cell lymphoma. It has three separate subtypes of its own. It is generally an aggressive disease, and frontline chemotherapy generally results in a cure about 50 percent of the time. There are two chemotherapy regimens and drugs involved in frontline therapy.
The R-CHOP regimen includes:
The EPOCH regimen includes:
Follicular lymphoma is an indolent B-cell disease. It is sometimes treated with the R-CHOP regimen mentioned above, but that is not used very often against this disease. Sometimes a patient simply receives Rituxan, other times just radiotherapy, and other times nothing at all. There is another two-drug combination being used with greater and greater frequency in indolent B-cell lymphomas: Rituxan plus Treanda (bendamustine).
There are three primary combination chemotherapy regimens used in the treatment of most cases of Hodgkin's lymphoma.
The ABVD regimen includes:
The Stanford V regimen includes:
The BEACOPP regimen includes:
Those are frontline treatments. In the event Hodgkin's recurs in a patient, he or she may receive the antibody drug conjugate Adcetris.